المؤلفون: Yap, TA, Krebs, MG, Postel-Vinay, S, El-Khouiery, A, Soria, J-C, Lopez, J, Berges, A, Cheung, SYA, Irurzun-Arana, I, Goldwin, A, Felicetti, B, Jones, GN, Lau, A, Frewer, P, Pierce, AJ, Clack, G, Stephens, C, Smith, SA, Dean, E, Hollingsworth, SJ

المساهمون: Lopez, Juanita

مصطلحات موضوعية: Antineoplastic Combined Chemotherapy Protocols, Ataxia Telangiectasia Mutated Proteins, Carboplatin, Humans, Indoles, Maximum Tolerated Dose, Morpholines, Neoplasms, Neutropenia, Nuclear Proteins, Protein Kinase Inhibitors, Pyrimidines, Sulfonamides, Sulfoxides, Thrombocytopenia

جغرافية الموضوع: United States

وصف الملف: Print; 5224; application/pdf

العلاقة: 1078-0432.CCR-21-1032; Clinical Cancer Research, 2021, 27 (19), pp. 5213 - 5224; https://repository.icr.ac.uk/handle/internal/5802Test

الإتاحة: https://doi.org/10.1158/1078-0432.CCR-21-1032Test
https://repository.icr.ac.uk/handle/internal/5802Test

المؤلفون: Krebs, M., Lopez, J., El-Khoueiry, A., Bang, Y.-J., Postel-Vinay, S., Abidah, W., Im, S.-A., Khoja, L.T., Standifer, N., Jones, G.N., Marco-Casanova, P., Frewer, P., Berges, A., Cheung, A., Stephens, C., Felicetti, B., Dean, E., Pierce, A., Hollingsworth, S.

المصدر: Annals of Oncology ; volume 29, page viii135 ; ISSN 0923-7534

مصطلحات موضوعية: Oncology, Hematology

الإتاحة: https://doi.org/10.1093/annonc/mdy279.401Test
https://api.elsevier.com/content/article/PII:S0923753419488807?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0923753419488807?httpAccept=text/plainTest
http://academic.oup.com/annonc/article-pdf/29/suppl_8/mdy279.401/26138472/mdy279.401.pdfTest

المؤلفون: Yap, T. A., Krebs, Matthew G, Postel-Vinay, S., El-Khoueiry, A, Soria, J. C., Lopez, J., Berges, A., Cheung, S. Y. A., Irurzun-Arana, I., Goldwin, A., Felicetti, B., Jones, G. N., Lau, A., Frewer, P., Pierce, A. J., Clack, G., Stephens, C., Smith, S. A., Dean, E, Hollingsworth, S. J.

المساهمون: Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center

العلاقة: https://dx.doi.org/10.1158/1078-0432.Ccr-21-1032Test; Yap TA, Krebs MG, Postel-Vinay S, El-Khouiery A, Soria J-C, Lopez J, et al. Ceralasertib (AZD6738), an oral ATR kinase inhibitor, in combination with carboplatin in patients with advanced solid tumors: a Phase I study. Clin Cancer Res. 2021 Jul 22;clincanres.1032.2021.; http://hdl.handle.net/10541/624454Test; Clinical Cancer Research

الإتاحة: https://doi.org/10.1158/1078-0432.Ccr-21-1032Test
http://hdl.handle.net/10541/624454Test

المؤلفون: Berges, A, Cheung, A, Pierce, A, Dean, E, Felicetti, B, Standifer, N, Smith, S, Yates, J, Lau, A, Stephens, C, Krebs, Matthew G, Harrington, K, Hollingsworth, S

المساهمون: Quantitative Clinical Pharmacology, Early Clinical Development, IMED Biotech Unit, AstraZeneca, Cambridge

العلاقة: https://dx.doi.org/10.1158/1538-7445.AM2018-CT118Test; Berges A, Cheung SYA, Pierce AJ, Dean E, Felicetti B, Standifer N, et al. PK-biomarker-safety modelling aids choice of recommended phase II dose and schedule for AZD6738 (ATR inhibitor). Cancer Res. 2018;78(13).; http://hdl.handle.net/10541/622035Test; Cancer Research

الإتاحة: https://doi.org/10.1158/1538-7445.AM2018-CT118Test
http://hdl.handle.net/10541/622035Test

المؤلفون: Krebs, Matthew G, Lopez, J, El-Khoueiry, A, Bang, Y, Postel-Vinay, S, Abida, W, Carter, Louise, Xu, W, Im, S, Pierce, A, Frewer, P, Berges, A, Cheung, A, Stephens, C, Felicetti, B, Dean, E, Hollingsworth, S

المساهمون: The Christie NHS Foundation Trust and The University of Manchester Manchester

العلاقة: https://dx.doi.org/10.1158/1538-7445.AM2018-CT026Test; Krebs MG, Lopez J, El-Khoueiry A, Bang Y-J, Postel-Vinay S, Abida W, et al. Phase I study of AZD6738, an inhibitor of ataxia telangiectasia Rad3-related (ATR), in combination with olaparib or durvalumab in patients (pts) with advanced solid cancers. Cancer Res. 2018;78(13).; http://hdl.handle.net/10541/622034Test; Cancer Research

الإتاحة: https://doi.org/10.1158/1538-7445.AM2018-CT026Test
http://hdl.handle.net/10541/622034Test

المؤلفون: Krebs, Matthew G, Lopez, J, El-Khoueiry, A, Bang, Y, Postel-Vinay, S, Abidah, W, Im, S, Khoja, L, Standifer, N, Jones, G, Marco-Casanova, P, Frewer, P, Berges, A, Cheung, A, Stephens, C, Felicetti, B, Dean, E, Pierce, A, Hollingsworth, S

المساهمون: Phase I Unit, The Christie NHS Foundation Trust, Manchester, UK

العلاقة: https://dx.doi.org/10.1093/annonc/mdy279.401Test; Krebs M, Lopez J, El-Khoueiry A, Bang YJ, Postel-Vinay S, Abidah W, et al. 413PD Phase I clinical and translational evaluation of AZD6738 in combination with durvalumab in patients (pts) with lung or head and neck carcinoma. Ann Oncol. 2018;29(suppl_8):135.; http://hdl.handle.net/10541/621801Test; Annals of Oncology

الإتاحة: https://doi.org/10.1093/annonc/mdy279.401Test
http://hdl.handle.net/10541/621801Test